Patents Assigned to New York Blood Center, Inc.
  • Publication number: 20120111807
    Abstract: Disclosed herein are centrifuge-free self-contained systems for aseptically separating components of whole blood comprising at least one cassette for receiving whole blood; at least one red blood cell exclusion filter; at least one leukocyte reduction filters; at least one platelet exclusion filter; a plurality of product cassettes; and optionally a plurality of pumps and valves; and wherein the filters, pumps, valves, and cassettes are fluidly connected by tubing and the system does not include a centrifuge. Also disclosed are methods for obtaining blood components using the system.
    Type: Application
    Filed: November 8, 2011
    Publication date: May 10, 2012
    Applicant: NEW YORK BLOOD CENTER, INC.
    Inventors: Christoper D. Hillyer, Beth H. Shaz
  • Publication number: 20120109677
    Abstract: Disclosed herein is a method for increasing the efficiency and reducing cost of the blood donation, processing and storage by pre-screening candidate donors for blood type and only collecting blood from donors having a needed blood type. Also disclosed are methods and systems for rapid determination of blood type of a blood donor prior to the initiation of the blood donation process.
    Type: Application
    Filed: October 31, 2011
    Publication date: May 3, 2012
    Applicant: New York Blood Center, Inc.
    Inventor: Christoper D. Hillyer
  • Publication number: 20120100150
    Abstract: Disclosed herein are neutralizing antibodies with cross-neutralizing activity and cross-protective effects against divergent stains of influenza virus, which are specific for an epitope having at least 90% homology to amino acids +72-115 of the HA1 domain of H5N1 influenza virus hemagglutinin.
    Type: Application
    Filed: October 20, 2011
    Publication date: April 26, 2012
    Applicant: NEW YORK BLOOD CENTER, INC.
    Inventors: Shibo Jiang, Lanying Du, Yusen Zhou
  • Publication number: 20120100979
    Abstract: Described herein are retention systems comprising an elastic member coupled to at least one securing member, a centrifuge bucket, and at least one item in the centrifuge bucket. The elastic member is attachable to at least two points on said centrifuge bucket thereby retaining the at least one item within the centrifuge bucket. Methods of using these systems are also described.
    Type: Application
    Filed: October 26, 2010
    Publication date: April 26, 2012
    Applicant: NEW YORK BLOOD CENTER, INC.
    Inventor: Dennis Chin
  • Patent number: 8148320
    Abstract: Provided are purified compounds comprising SEQ ID NO:1, where the tyrosine at residue (10) is phosphorylated. Also provided are purified compounds comprising SEQ ID NO:1, where the amino acid sequence of the compound is less than 400 amino acids. Additionally provided are methods of determining whether an agent is a candidate inhibitor of an AbI kinase. Further provided are methods of inhibiting an AbI kinase. Also provided are methods of treating a patient having a condition characterized by a mutant AbI kinase. Additionally provided are methods of treating a patient at risk for a condition characterized by a mutant AbI kinase. Methods of labeling an AbI kinase are also provided. Additionally, methods of isolating an AbI kinase from a tissue are provided.
    Type: Grant
    Filed: November 29, 2006
    Date of Patent: April 3, 2012
    Assignee: New York Blood Center, Inc.
    Inventors: Leszek Kotula, Xiaoling Xiong
  • Patent number: 8110719
    Abstract: Genetically engineered conditional knock-out mice having conditional disruption of the Abi1/Hssh3bp1 gene are disclosed along with methods of making and using same.
    Type: Grant
    Filed: April 27, 2009
    Date of Patent: February 7, 2012
    Assignee: New York Blood Center, Inc.
    Inventor: Leszek Kotula
  • Publication number: 20110091911
    Abstract: Disclosed herein are antibodies, systems and methods for assessing the risk of hemolysis following a blood transfusion with crossmatch incompatible blood. The disclosure provides a method for determining the relative hemolytic index and therefore the risk of post-transfusion hemolysis for said patient.
    Type: Application
    Filed: October 20, 2010
    Publication date: April 21, 2011
    Applicant: New York Blood Center, Inc.
    Inventor: Gregory R. Halverson
  • Patent number: 7928084
    Abstract: Disclosed are methods and compositions for preventing and treating conditions associated with platelet aggregation, comprising administering a therapeutically effective amount of a composition that modifies the interaction of DNAJC10 with ?IIb?3 in a megakaryocyte, thereby altering the expression of ?IIb?3 on the surface of the megakaryocyte.
    Type: Grant
    Filed: August 19, 2009
    Date of Patent: April 19, 2011
    Assignee: New York Blood Center, Inc.
    Inventors: W. Beau Mitchell, Mahmoud Yazdani Abyaneh, Amanda Chen
  • Publication number: 20100266634
    Abstract: The present invention relates to a method for potentiating a specific immune response to an antigen in a mammal in need thereof. The method comprises administering to the mammal an effective amount of Ov-ASP, or at least one subunit of Ov-ASP, and an antigenic moiety.
    Type: Application
    Filed: February 18, 2010
    Publication date: October 21, 2010
    Applicant: NEW YORK BLOOD CENTER, INC.
    Inventors: Angus J. MacDonald, Sara Lustigman
  • Publication number: 20100130430
    Abstract: Provided are constrained peptides that inhibit HIV assembly. Pharmaceutical compositions comprising the above peptides are also provided. Additionally provided are methods of inhibiting replication of a capsid-containing virus in a cell. Also provided are methods of treating a mammal infected with a capsid-containing virus. Further provided are methods of treating a mammal at risk for infection with a capsid-containing virus. Methods of making the above peptides are additionally provided, as are uses of the above peptides and pharmaceutical compositions.
    Type: Application
    Filed: October 2, 2007
    Publication date: May 27, 2010
    Applicant: New York Blood Center, Inc
    Inventors: Asim Kumar Debnath, Hongtao Zhang, Qian Zhao
  • Patent number: 7629443
    Abstract: The present invention provides an isolated antibody capable of binding to the receptor-binding domain of the spike protein of the severe acute respiratory syndrome-associated coronavirus (SARS-CoV) so as to competitively inhibit the binding of the SARS-CoV to host cells. These mAbs or substances can be used: 1) as passive-immunizing agents for prevention of SARS-CoV infection; 2) as biological reagents for diagnosis of SARS-CoV infection; 3) as immunotherapeutics for early treatment of SARS-CoV infection; and 4) as probes for studying the immunogenicity, antigenicity, structure, and function of the SARS-CoV S protein.
    Type: Grant
    Filed: February 8, 2006
    Date of Patent: December 8, 2009
    Assignee: New York Blood Center, Inc.
    Inventors: Shibo Jiang, Yuxian He
  • Publication number: 20090104612
    Abstract: Disclosed herein are nucleic acid molecules which permit the accurate and direct determination of blood groups based on the presence of certain genes. A method of determining blood groups is also provided.
    Type: Application
    Filed: October 20, 2008
    Publication date: April 23, 2009
    Applicant: New York Blood Center, Inc.
    Inventors: Marion Reid, Asok Chaudhuri
  • Patent number: 7348164
    Abstract: The present invention provides a method to diagnostically detect the variants of a given pathogen, such as HIV, hepatitis C, hepatitis B (HBV), Parvovirus B19, etc., with the use of a single detection probe.
    Type: Grant
    Filed: April 17, 2002
    Date of Patent: March 25, 2008
    Assignee: The New York Blood Center, Inc.
    Inventors: Linda Andrus, Carmen Nicola Nichols
  • Publication number: 20070082035
    Abstract: Methods for maintaining a low vaginal pH, preventing the propagation of toxic shock syndrome toxin 1 production during menstruation, preventing the shedding and dissemination of a herpesvirus and treating herpes lesions comprising administering to a human a formulation comprising a pharmaceutically effective amount of an insoluble micronized form of cellulose acetate phthalate or a cellulose acetate phthalate film or a cellulose acetate phthalate porous sponge. Also a method of treating Candida albicans infection comprising administering to a human female a pharmaceutically effective amount of a composition comprising micronized cellulose acetate phthalate and miconazole nitrate.
    Type: Application
    Filed: October 3, 2006
    Publication date: April 12, 2007
    Applicant: NEW YORK BLOOD CENTER, INC.
    Inventors: Alexander Neurath, Nathan Strick, Yun-Yao Li
  • Patent number: 7169547
    Abstract: A therapeutic product formed from a high concentration of white blood cells having a high degree of cell viability. The white blood cells are sequestered from their normal population presence in whole blood by placing the blood into a container and preventing coagulation of the blood, separating the blood into two components, one of which is extremely rich in white blood cells through the use of a reagent and centrifugation, sequestering the white cell concentration, and freezing the white cells.
    Type: Grant
    Filed: May 15, 2001
    Date of Patent: January 30, 2007
    Assignee: New York Blood Center, Inc.
    Inventors: Pablo Rubinstein, Philip Henry Coelho, Cladd E. Stevens
  • Publication number: 20060062866
    Abstract: A complex comprising a starch and an active anti-HIV-1 or anti-HIV-2 ingredient of pomegranate juice that is adsorbed on the starch when the starch is in a water insoluble form. The complex inhibits HIV-1 or HIV-2 infection and blocks the binding of HIV-1 or HIV-2 to the CD4 receptor and the CCR5 and CXCR4 coreceptors. The complex is used in a method of preventing HIV-1 or HIV-2 infection comprising administering to a mucous membrane of a human a pharmaceutically effective anti-HIV-1 or anti-HIV-2 amount of the complex.
    Type: Application
    Filed: September 9, 2005
    Publication date: March 23, 2006
    Applicant: NEW YORK BLOOD CENTER, INC.
    Inventors: Alexander Neurath, Nathan Strick, Yun-Yao Li
  • Publication number: 20050070501
    Abstract: A soft, pliable cellulose acetate phthalate (CAP)—hydroxypropyl cellulose (HPC) composite film is provided which is generated by casting from organic solvent mixtures containing ethanol. The film rapidly reduces the infectivity of several sexually transmitted disease pathogens, including the human immunodeficiency virus (HIV-1), herpesvirus (HSV), non-viral sexually transmitted disease pathogens (such as Neisseria gonorrhoeae, Haemophilus ducreyi, Chlamydia trachomatis and Treponema pallidum) and bacteria associated with bacterial vaginosis (BV). The film is converted into a gel/cream and thus does not have to be removed following application and use. In addition to being a topical microbicide, the film can be employed for the mucosal delivery of pharmaceuticals other than cellulose acetate phthalate.
    Type: Application
    Filed: August 16, 2004
    Publication date: March 31, 2005
    Applicant: NEW YORK BLOOD CENTER, INC.
    Inventors: Alexander Neurath, Nathan Strick, Yun-Yao Li
  • Patent number: 6838240
    Abstract: The present invention provides a method for diagnosing Bloom's syndrome (BS) as well as determining whether a subject is a carrier of a mutated BLM gene. The present invention also provides one or more single-stranded nucleic acid probes and antibodies which may be formulated in kits, and used for diagnosing BS or determining whether a human subject is a carrier of a mutated BLM gene. In addition, the present invention provides a method for treating or preventing the onset of BS in a subject in need of such treatment or prevention, as well as vectors and stem cells useful for such treatment or prevention. The present invention also provides a purified and isolated nucleic acid encoding an enzymatically active BLM protein, a vector comprising this nucleic acid, a cell stably transformed with this vector, as well as a method for producing recombinant, enzymatically active BLM protein. A purified, enzymatically active BLM protein is also provided by the present invention.
    Type: Grant
    Filed: January 2, 2001
    Date of Patent: January 4, 2005
    Assignees: New York Blood Center, Inc., University of Cincinnati
    Inventors: Nathan Ellis, James German, Joanna Groden
  • Patent number: 6727240
    Abstract: A method of preventing HIV-1 or HIV-2 infection by administering to a human a pharmaceutically effective anti-HIV-1 or anti-HIV-2 amount of a tin or silicon protoporphyrin IX or tin or silicon mesoporphyrin IX, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: October 21, 1994
    Date of Patent: April 27, 2004
    Assignee: New York Blood Center, Inc.
    Inventors: Alexander R. Neurath, Shibo Jiang, Asim Kumar Debnath
  • Patent number: 6723322
    Abstract: The present invention provides a method for inducing angiogenesis in a tissue, by contacting the tissue with an amount of Ov-ASP effective to induce angiogenesis in the tissue. The present invention further provides a method for screening for an anti-Ov-ASP factor, by contacting a factor of interest with Ov-ASP, and assessing the ability of the factor to inhibit angiogenic activity of Ov-ASP. Additionally, the present invention provides a method for inhibiting angiogenesis in a subject.
    Type: Grant
    Filed: April 3, 2000
    Date of Patent: April 20, 2004
    Assignees: New York Blood Center, Inc., Case Western Reservei University, UAB Research Foundation
    Inventors: Sara Lustigman, Eric Pearlman, Thomas R. Unnasch